Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:KYMR NASDAQ:PTGX NASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.64$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$86.26+4.3%$84.38$28.06▼$103.00$6.80B2.06511,738 shs426,842 shsPTGXProtagonist Therapeutics$103.97+4.8%$99.17$41.28▼$107.84$6.38B1.89657,779 shs989,856 shsSNDXSyndax Pharmaceuticals$20.65+2.7%$23.06$8.58▼$25.59$1.78B0.411.64 million shs1.70 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.31%+71.90%+118.08%KYMRKymera Therapeutics+4.29%+5.83%+1.16%+13.59%+201.91%PTGXProtagonist Therapeutics+4.80%+5.53%+1.05%+28.88%+147.49%SNDXSyndax Pharmaceuticals+2.74%+0.10%-14.99%+2.48%+94.08%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$115.07$114.64$47.86▼$115.13$6.73B0.251.50 million shs14.67 million shsKYMRKymera Therapeutics$86.26+4.3%$84.38$28.06▼$103.00$6.80B2.06511,738 shs426,842 shsPTGXProtagonist Therapeutics$103.97+4.8%$99.17$41.28▼$107.84$6.38B1.89657,779 shs989,856 shsSNDXSyndax Pharmaceuticals$20.65+2.7%$23.06$8.58▼$25.59$1.78B0.411.64 million shs1.70 million shs10 Best Stocks to Own in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx0.00%0.00%+0.31%+71.90%+118.08%KYMRKymera Therapeutics+4.29%+5.83%+1.16%+13.59%+201.91%PTGXProtagonist Therapeutics+4.80%+5.53%+1.05%+28.88%+147.49%SNDXSyndax Pharmaceuticals+2.74%+0.10%-14.99%+2.48%+94.08%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.11Hold$111.87-2.78% DownsideKYMRKymera Therapeutics 2.96Moderate Buy$118.1036.91% UpsidePTGXProtagonist Therapeutics 2.80Moderate Buy$113.699.35% UpsideSNDXSyndax Pharmaceuticals 2.92Moderate Buy$42.64106.47% UpsideCurrent Analyst Ratings BreakdownLatest SNDX, ACLX, KYMR, and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026KYMRKymera Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$106.005/6/2026PTGXProtagonist Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$120.00 ➝ $137.005/6/2026PTGXProtagonist Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$112.00 ➝ $118.005/1/2026SNDXSyndax Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$35.00 ➝ $37.004/30/2026KYMRKymera Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$119.004/29/2026ACLXArcellx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral4/27/2026ACLXArcellx Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/21/2026KYMRKymera Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ACLXArcellx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$22.29M301.95N/AN/A$6.96 per share16.53KYMRKymera Therapeutics$39.21M180.97N/AN/A$18.72 per share4.61PTGXProtagonist Therapeutics$46.02M145.29N/AN/A$9.83 per share10.58SNDXSyndax Pharmaceuticals$172.35M10.62N/AN/A$0.47 per share43.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$228.93M-$4.07N/AN/AN/A-1,027.26%-55.42%-36.24%5/7/2026 (Estimated)KYMRKymera Therapeutics-$311.35M-$3.57N/AN/AN/A-611.94%-24.71%-22.05%N/APTGXProtagonist Therapeutics-$130.15M-$2.05N/AN/AN/A-282.83%-19.89%-18.40%N/ASNDXSyndax Pharmaceuticals-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%N/ALatest SNDX, ACLX, KYMR, and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ACLXArcellx-$1.13N/AN/AN/A$6.07 millionN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.65$0.05+$0.70$0.05$11.70 million$56.37 million4/30/2026Q1 2026KYMRKymera Therapeutics-$0.89-$0.71+$0.18-$0.71$8.27 million$34.37 million4/30/2026Q1 2026SNDXSyndax Pharmaceuticals-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million2/26/2026Q4 2025ACLXArcellx-$1.01-$1.01N/A-$1.01$13.40 million$1.65 million2/26/2026Q4 2025KYMRKymera Therapeutics-$0.77-$0.97-$0.20-$0.97$14.80 million$2.87 million2/26/2026Q4 2025SNDXSyndax Pharmaceuticals-$0.64-$0.78-$0.14-$0.78$64.75 million$68.73 million2/25/2026Q4 2025PTGXProtagonist Therapeutics-$0.53-$0.69-$0.16-$0.69$14.92 million$7.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.444.44KYMRKymera TherapeuticsN/A10.8110.81PTGXProtagonist TherapeuticsN/A12.7112.71SNDXSyndax Pharmaceuticals8.265.474.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%KYMRKymera TherapeuticsN/APTGXProtagonist Therapeutics98.63%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACLXArcellx8.35%KYMRKymera Therapeutics16.01%PTGXProtagonist Therapeutics4.90%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8058.48 million53.60 millionOptionableKYMRKymera Therapeutics17082.26 million69.09 millionOptionablePTGXProtagonist Therapeutics12064.31 million61.15 millionOptionableSNDXSyndax Pharmaceuticals11088.61 million84.98 millionOptionableSNDX, ACLX, KYMR, and PTGX HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)May 6 at 4:01 PM | globenewswire.comSyndax Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 5 at 7:15 PM | seekingalpha.comBiotech Momentum Builds As Syndax Pharmaceuticals Draws Market AttentionMay 5 at 3:23 PM | kalkinemedia.comKBank of America Securities Reaffirms Their Buy Rating on Syndax Pharmaceuticals (SNDX)May 5 at 3:23 PM | theglobeandmail.comHC Wainwright Has Optimistic Outlook of SNDX Q2 EarningsMay 5 at 8:32 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 6.6% Following Analyst UpgradeMay 4 at 10:17 AM | marketbeat.comHC Wainwright Has Bullish Outlook for SNDX FY2030 EarningsMay 4 at 1:35 AM | americanbankingnews.comHC Wainwright Has Optimistic Outlook of SNDX FY2030 EarningsMay 4 at 1:33 AM | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 7.1% - Should You Sell?May 3, 2026 | americanbankingnews.comSyndax Slide Puts Nasdaq Index Biotech in FocusMay 2, 2026 | kalkinemedia.comKSyndax Pharmaceuticals Inc (SNDX) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ...May 2, 2026 | finance.yahoo.comSyndax (SNDX) Narrows Losses as Revuforj and Niktimvo Gain Traction - What’s Really Shifting?May 2, 2026 | finance.yahoo.comSyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 7.1% - Time to Sell?May 1, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $37.00May 1, 2026 | marketbeat.comSyndax: Q1 Earnings SnapshotApril 30, 2026 | stamfordadvocate.comSSyndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comSyndax Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings ResultsApril 30, 2026 | marketbeat.comSyndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue EstimatesApril 30, 2026 | zacks.comSyndax Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comNuvation Bio Inc. (NUVB) Reports Next Week: Wall Street Expects Earnings GrowthApril 27, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSNDX, ACLX, KYMR, and PTGX Company DescriptionsArcellx NASDAQ:ACLX$115.07 0.00 (0.00%) As of 04/28/2026Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Kymera Therapeutics NASDAQ:KYMR$86.26 +3.55 (+4.29%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$86.24 -0.02 (-0.02%) As of 05:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Protagonist Therapeutics NASDAQ:PTGX$103.97 +4.76 (+4.80%) Closing price 05/6/2026 04:00 PM EasternExtended Trading$104.12 +0.16 (+0.15%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.Syndax Pharmaceuticals NASDAQ:SNDX$20.65 +0.55 (+2.74%) As of 05/6/2026 04:00 PM EasternSyndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Boarding Passes Now Being Issued for the Ultimate eVTOL Arbitrage DigitalOcean’s AI Surge: How Far Can This Rally Go? Apple Talks Just Changed Everything for Intel Consolidate or Die: Is Rivian The Ultimate Takeover Target? Years in the Making, AMD’s Upside Movement Has Just Begun Capital One’s Big Bet Faces Rising Credit Risk Western Digital: The Storage Behemoth Skyrocketing on AI Demand Old Money, New Tech: Western Union's Crypto Reboot Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
